Suchergebnisse - "Scott, Clare L"

PubPharm (8)

1

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors

enthalten in: British journal of cancer | 2022

von Cremona, M. | Vandenberg, C. | Farrelly, A. | +12

2

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

enthalten in: Nature communications | 2021

von Swisher, E. | Kwan, T. | Oza, A. | +31

3

RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers

enthalten in: Cancer research | 2020

von Krais, J. | Wang, Y. | Bernhardy, A. | +5

CommentIn: Cancer Res. 2020 Jul 1;80(13):2720-2721. - PMID 32616507

4

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

enthalten in: Cancer discovery | 2019

von Lin, K. | Harrell, M. | Oza, A. | +22

5

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

enthalten in: Nature communications | 2018

von Kondrashova, O. | Topp, M. | Nesic, K. | +128

6

Targeting DNA repair : the genome as a potential biomarker

enthalten in: The Journal of pathology | 2018

von Nesic, K. | Wakefield, M. | Kondrashova, O. | +2

7

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1) : an international, multicentre, open-label, phase 2 trial

enthalten in: The Lancet. Oncology | 2017

von Swisher, E. | Lin, K. | Oza, A. | +28

CommentIn: Lancet Oncol. 2017 Jan;18(1):8-9. - PMID 27908593

8

Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts

enthalten in: Molecular oncology | 2014

von Topp, M. | Hartley, L. | Cook, M. | +20

1
[1]